The forecast for the import of Phenazone (Antipyrin) to China indicates a gradual increase from 2024 to 2028, starting at 258.24 thousand USD in 2024 and reaching 265.34 thousand USD by 2028. In 2023, the import value was unnoted, indicating reliance on forecast data from 2024 onward. The year-on-year growth is approximately 0.7% each year until 2028. Over the five-year period, the compound annual growth rate (CAGR) is modest. Such consistent growth suggests stable, albeit slow, expansion in demand for Phenazone imports.
Future trends to watch will include potential increases in production cost due to changes in global raw material prices, regulatory shifts affecting pharmaceutical imports, and any significant changes in China's healthcare policy that might alter the demand trajectory for Phenazone or its alternatives.
